All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Tuberculosis (TB) remains the leading global cause of death by a single infectious agent; it caused approximately 1.6 million deaths in 2017. An estimated 10 million people developed the disease, of whom 6.4 million (64%) were notified\[[@pone.0226507.ref001]\]. Additionally, of the 558,000 estimated cases of rifampicin- and isoniazid-resistant TB (multidrug-resistant TB---MDR-TB)/rifampin-resistant TB (RR-TB), a total of 139,114 people (87%) received the second-line regimen, and the proportion of MDR-TB cases with extensively drug-resistant TB (XDR-TB) defined as MDR-TB plus resistance to at least one drug in both of the two most important classes of medicines in an MDR-TB regimen: fluoroquinolones and second-line injectable agents (amikacin, capreomycin or kanamycin) was 8.5% (95% CI: 6.2--11%) \[[@pone.0226507.ref001]\].

The innumerable efforts to end the global TB epidemic have resulted in remarkable developments in research focused on multiple aspects of the disease. Unfortunately, we should rely on poor diagnostic, therapeutic, and preventive options. However, it is estimated that with the current strategies for TB control, the goals of reducing the number of deaths by 95%, reducing the incidence rate by 90% and increasing the cure rate of patients receiving first-line treatment to 90% between 2015 and 2035 will not be reached without intensifying research and development\[[@pone.0226507.ref002]\]. It is also necessary to strengthen health systems' ability to detect cases early and to improve the quality of care, diagnosis and treatment of people with TB\[[@pone.0226507.ref003]\].

TB treatment coverage is one of the ten priority indicators for achieving the goals of the End TB Strategy, and it has increased from 51% in 2013 to 70% in 2017\[[@pone.0226507.ref002],[@pone.0226507.ref004]\]. However, the treatment success rate has decreased from 86% in 2013 to 82% in 2016; in MDR-TB/RR-TB and XDR-TB cases, the success rate remains low: 55% and 34% in 2015\[[@pone.0226507.ref001]\]. This situation could be related to the limited evaluation of treatment outcomes in countries with limited resources and to the presence of factors that affect the outcome of TB treatment. Exhaustive estimates of TB treatment outcomes are needed to improve the programmatic management of TB. Therefore, this review with meta-analysis was performed to produce pooled estimates of global TB treatment outcomes and to analyze the predictive factors of successful TB treatment.

Methods {#sec006}
=======

This review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) in February 2019 under number CRD42019121512.

Search strategy {#sec007}
---------------

PubMed, Medline, Embase, ProQuest, Scopus and Scielo were searched for publications of the last 6 years that is, published between January 2014 and November 2019 that reported the results of treatment for pulmonary tuberculosis and the factors that influenced these results. We also searched other sources, such as Google and Google Scholar, and bibliographies to obtain additional references. Our search contained the following terms: tuberculosis, predictive factors, risk factors and treatment outcomes (tuberculosis AND (risk factors OR associated factors OR predictive factors OR characteristics) AND (treatment results OR treatment outcome OR successful treatment OR unsuccessful treatment OR unfavorable outcome OR (poverty OR poor)) AND tuberculosis treatment results) in English, Spanish and Portuguese. Trying to include as many publications as possible about our topic of interest. Approval from the ethics committee was not required.

Data extraction and definitions {#sec008}
-------------------------------

The step-by-step selection of the studies is described in [Fig 1](#pone.0226507.g001){ref-type="fig"}. All article titles and abstracts were evaluated by two investigators (JR and PP), including all the studies that reported quantitative measurements of the results of tuberculosis treatment, and these results were clearly described according to the WHO criteria. For cases of drug-sensitive TB, only studies that clearly described patients receiving the standard treatment for tuberculosis recommended by the WHO known as short-term treatment (6 months) that includes 4 drugs. Studies that reported exclusively on extrapulmonary tuberculosis and those that did not allow the adequate extraction of quantitative data were not included. The full text of articles identified as relevant by any of the reviewers was read.

![PRISMA flow chart indicating the result of literature search.](pone.0226507.g001){#pone.0226507.g001}

To determine which full-text articles met the inclusion criteria, two investigators (JR and PP) reviewed all full-text articles, and a third investigator (NC) reviewed a random selection of studies. In cases of disagreement, the two investigators discussed the article until they agreed. One investigator (JR) extracted data from all included studies. The second investigator (NC) independently extracted all numerical data regarding the estimation of the main effect to validate the first review. If data from the same cohort were included in several articles, the article with the most complete data was included. For each included study, detailed information was collected on the design, publication year, country, study population, sample size, definition and measurement of treatment outcomes and associated factors.

Validity assessment {#sec009}
-------------------

The quality of the included studies was evaluated according to the Newcastle-Ottawa quality assessment scale\[[@pone.0226507.ref005]\]. It evaluates quality based on the content, design and ease of use of the data for meta-analysis. Two investigators (JR and PP) independently evaluated the quality of the studies, classifying each study as being of either good, acceptable or low quality.

Statistical methods and data synthesis {#sec010}
--------------------------------------

TB treatment outcome measures were evaluated as the percentage of successful and unsuccessful results among all patients who initiated anti-TB therapy. The results of treatment were defined according to WHO criteria\[[@pone.0226507.ref006]\]. Successful outcomes were those in which patients met the definition of \'cure\' or 'treatment completion'. Unsuccessful outcomes were those in which patients met the definitions of death, default, failure or transfer. The subgroup analysis was performed by continent (Africa, America, Asia, Europe and Oceania), people living with HIV, children (1 to 15 years of age) and MDR/XDR-TB.

The associations of different variables, such as age (\<65 years---66 years or older), sex (male---female), area of residence (rural---urban), type of case (new---previously treated), form of TB (pulmonary---extrapulmonary), alcohol consumption (yes---no), smoking (yes---no), HIV status (positive---negative), diabetes (yes---no), baseline sputum smear (positive---negative), and sputum smear microscopy two months after treatment (positive---negative), with the TB treatment outcome were measured. It was not possible to test the association from nutritional status, of educational level or socioeconomic status with TB treatment because these variables were evaluated differently in the studies depending on the country or region of origin. The influence of the health facility providing treatment on the results of TB treatment was not addressed in the studies included in this review.

Because most of the studies did not examine the association between these variables and successful treatment outcome as the main effect, unadjusted odds ratios (OR) and 95% confidence intervals (CI) were calculated as estimates of this association. After a table of results was created for each of the analyses, a random effects model was used to calculate pooled ORs and 95% CIs as there were high levels of heterogeneity in the study populations. Statistical heterogeneity was assessed using the I^2^ statistic. Publication bias was assessed using a funnel plot. All statistical analyses were performed in MedCalc® version 19.03.

Results {#sec011}
=======

As indicated in [Fig 1](#pone.0226507.g001){ref-type="fig"}, a total of 1,432 articles were identified. Of these, 992 were not duplicated; 807 of those were excluded after the title and abstract were evaluated, and 185 underwent a detailed review of the full text. A total of 151 studies with 1,550,449 patients with TB from 59 countries distributed among 5 continents met the criteria for inclusion in this review ([Table 1](#pone.0226507.t001){ref-type="table"}).

10.1371/journal.pone.0226507.t001

###### Distribution of patients with TB in the continents.

![](pone.0226507.t001){#pone.0226507.t001g}

  Continent          No. Countries   No. Studies   \%      Pacientes   \%
  ------------------ --------------- ------------- ------- ----------- -------
  Africa             15              47            31.1    164,091     10.6
  America            6               20            13.2    716,992     46.2
  Asia               19              58            38.4    357,163     23.0
  Europe             12              18            11.9    302,557     19.5
  Oceania            5               5             3.3     6,926       0.4
  Intercontinental   3               3             2.0     2,740       0.2
  Total              60              151           100.0   1,550,469   100.0

In total, 95 of the 151 studies were retrospective cohort, 28 were cross-sectional, 25 were prospective cohort and 3 were case-control studies. Of the eligible studies, 91 reported treatment results in cases of TB in adults, 7 in children, 15 in patients coinfected with HIV and 38 in MDR/XDR-TB cases. These studies are detailed in [Table 2](#pone.0226507.t002){ref-type="table"}.

10.1371/journal.pone.0226507.t002

###### Characteristics of the included studies according to continent of origin and population studied.

![](pone.0226507.t002){#pone.0226507.t002g}

  Autor (Year)                                                 Country                                                                                       Study design   n        Success   \%     Quality / newcastle
  ------------------------------------------------------------ --------------------------------------------------------------------------------------------- -------------- -------- --------- ------ ---------------------
  **TB studies in Africa**                                                                                                                                                                            
    Adane K. et al (2018)\[[@pone.0226507.ref007]\]            Ethiopia                                                                                      RC             422      395       93,6   L
    Ali M. et al (2017)\[[@pone.0226507.ref008]\]              Somalia                                                                                       CS             385      315       81,8   L
    Amante T. et al (2015)\[[@pone.0226507.ref009]\]           Ethiopia                                                                                      CC             976      646       66,2   L
    Budgell E. et al (2016)\[[@pone.0226507.ref010]\]          South Africa                                                                                  RC             544      394       72,4   A
    Chidubem L. et al (2016)\[[@pone.0226507.ref011]\]         Nigeria                                                                                       RC             555      479       86,3   L
    Ejeta E. et al (2018)\[[@pone.0226507.ref012]\]            Ethiopia                                                                                      RC             4144     3532      85,2   G
    El-Shabrawy M. et al (2017)\[[@pone.0226507.ref013]\]      Egypt                                                                                         RC             480      384       80,0   L
    Ershova V. et al (2014)\[[@pone.0226507.ref014]\]          South Africa                                                                                  RC             741      617       83,3   L
    Esmael A. et al (2014)\[[@pone.0226507.ref015]\]           Ethiopia                                                                                      RC             717      425       59,3   L
    Gebrezgabiher G. et al (2016) \[[@pone.0226507.ref016]\]   Ethiopia                                                                                      RC             1537     1310      85,2   L
    Kosgei J. et al (2015)\[[@pone.0226507.ref017]\]           Kenya                                                                                         RC             16056    14318     89,2   G
    Mbatchou B. et al (2016)\[[@pone.0226507.ref018]\]         Cameroon                                                                                      RC             8902     6684      75,1   L
    Mhimbira F. et al (2016)\[[@pone.0226507.ref019]\]         Tanzania                                                                                      RC             4835     4006      82,9   L
    Mlotshwa M. et al (2016) \[[@pone.0226507.ref020]\]        South Africa                                                                                  RC             12742    10719     84,1   L
    Mugomeri E. et al (2017)\[[@pone.0226507.ref021]\]         Lesotho                                                                                       RC             812      577       71,1   A
    Muluye A. et al (2018)\[[@pone.0226507.ref022]\]           Ethiopia                                                                                      CS             995      905       91,0   L
    Nafae R. et al (2017)\[[@pone.0226507.ref023]\]            Egypt                                                                                         RC             280      231       82,5   G
    Nanzaluka F. et al (2019)\[[@pone.0226507.ref024]\]        Zambia                                                                                        RC             1724     985       57,1   L
    Nembot F. et al (2015)\[[@pone.0226507.ref025]\]           Cameroon                                                                                      RC             1286     1119      87,0   L
    Oshi S. et al (2014)\[[@pone.0226507.ref026]\]             Nigeria                                                                                       RC             1668     1268      76,0   G
    Peltzer K. et al (2014)\[[@pone.0226507.ref027]\]          South Africa                                                                                  PC             1196     695       58,1   L
    Saleh A. et al (2017) \[[@pone.0226507.ref028]\]           Yemen                                                                                         RC             273      227       83,2   A
    Ukwajaa N. et al (2014)\[[@pone.0226507.ref029]\]          Nigeria                                                                                       RC             929      796       85,7   L
    Wondale B. et al (2017)\[[@pone.0226507.ref030]\]          Ethiopia                                                                                      RC             1172     868       74,1   L
    Worku S. et al (2018)\[[@pone.0226507.ref031]\]            Ethiopia                                                                                      CS             985      672       68,2   G
    Yoko J. et al (2017)\[[@pone.0226507.ref032]\]             South Africa                                                                                  CS             229      176       76,9   L
    Zenebe T. et al (2016)\[[@pone.0226507.ref033]\]           Ethiopia                                                                                      RC             380      320       84,2   L
    Zenebe Y. et al (2016)\[[@pone.0226507.ref034]\]           Ethiopia                                                                                      CS             671      542       80,8   L
  **TB Studies in America**                                                                                                                                                                           
    Cailleaux M. et al (2017)\[[@pone.0226507.ref035]\]        Brazil                                                                                        RC             174      146       83,9   L
    Calle A. et al (2016)\[[@pone.0226507.ref036]\]            Colombia                                                                                      CS             837      645       77,1   A
    Djibuti M. et al (2014)\[[@pone.0226507.ref037]\]          U.S                                                                                           PC             202      155       76,7   L
    Lackey B. et al (2015)\[[@pone.0226507.ref038]\]           Peru                                                                                          PC             1233     1036      84,0   L
    Maciel E. et al (2015)\[[@pone.0226507.ref039]\]           Brazil                                                                                        CS             318465   222186    69,8   G
    Magee M. et al (2015)\[[@pone.0226507.ref040]\]            U.S                                                                                           PC             291      221       75,9   L
    Pereira J. Et al (2015)\[[@pone.0226507.ref041]\]          Brazil                                                                                        RC             421      362       86,0   L
    Reis-Santos B. et al (2015)\[[@pone.0226507.ref042]\]      Brazil                                                                                        CS             31578    23537     74,5   L
    Romanowski K. et al (2017)\[[@pone.0226507.ref043]\]       Canada                                                                                        RC             165      144       87,3   L
    Silva M. et al (2017)\[[@pone.0226507.ref044]\]            Brazil                                                                                        PC             220      172       78,2   L
    Snyder R. et al (2016)\[[@pone.0226507.ref045]\]           Brazil                                                                                        RC             6601     3585      54,3   L
    Viana P. et al (2016)\[[@pone.0226507.ref046]\]            Brazil                                                                                        CS             278674   204205    73,3   L
    Viegas A. et al (2016)\[[@pone.0226507.ref047]\]           Brazil                                                                                        PC             83       64        77,1   A
  **TB studies in Asia**                                                                                                                                                                              
    Ahmad T. et al (2017)\[[@pone.0226507.ref048]\]            Pakistan                                                                                      RC             493      468       94,9   L
    Ali K. et al (2015)\[[@pone.0226507.ref049]\]              Iran                                                                                          RC             167      143       85,6   A
    Alqahtani S. et al (2017)\[[@pone.0226507.ref050]\]        Saudi Arabia                                                                                  CS             1600     1338      83,6   L
    Atif M. et al (2014)\[[@pone.0226507.ref051]\]             Malaysia                                                                                      RC             336      226       67,3   L
    Babalik A. et al (2014)\[[@pone.0226507.ref052]\]          Turkey                                                                                        RC             23845    22412     94,0   L
    Chi C. et al (2015)\[[@pone.0226507.ref053]\]              China                                                                                         PC             16345    13349     81,7   A
    Choi H. et al (2014)\[[@pone.0226507.ref054]\]             Korea                                                                                         PC             669      335       50,1   L
    Gadoev J. et al (2015)\[[@pone.0226507.ref055]\]           Uzbekistan                                                                                    RC             107380   89622     83,5   L
    Hongguang C. et al (2015)\[[@pone.0226507.ref056]\]        China                                                                                         PC             1126     1066      94,7   L
    Jackson C. et al (2017)\[[@pone.0226507.ref057]\]          India                                                                                         RC             8415     7148      84,9   A
    Khaing P. et al (2018)\[[@pone.0226507.ref058]\]           Myanmar                                                                                       RC             13711    11066     80,7   L
    Khazaei S. et al (2016)\[[@pone.0226507.ref059]\]          Iran                                                                                          CS             510      424       83,1   G
    Kwon Y. et al (2014)\[[@pone.0226507.ref060]\]             Korea                                                                                         RC             2481     2333      94,0   L
    Liew S. et al (2015)\[[@pone.0226507.ref061]\]             Malaysia                                                                                      RC             21582    16824     78,0   L
    Lin Y. et al (2017)\[[@pone.0226507.ref062]\]              China                                                                                         CS             30277    26016     85,9   L
    Lo H. et al (2016)\[[@pone.0226507.ref063]\]               Taiwan                                                                                        RC             766      544       71,0   L
    Lwin Z. et al (2017)\[[@pone.0226507.ref064]\]             Myanmar                                                                                       RC             2975     2618      88,0   L
    Morishita F. et al (2017)\[[@pone.0226507.ref065]\]        Philippines                                                                                   RC             612      548       89,5   L
    Mukhtar F. et al (2016)\[[@pone.0226507.ref066]\]          Pakistan                                                                                      PC             614      434       70,7   L
    Mundra A. et al (2017)\[[@pone.0226507.ref067]\]           India                                                                                         RC             510      418       82,0   L
    Mundra A. et al (2017)\[[@pone.0226507.ref068]\]           India                                                                                         CC             275      187       68,0   L
    Ni W. et al (2016)\[[@pone.0226507.ref069]\]               China                                                                                         RC             1447     1349      93,2   L
    Piparva K. (2016)\[[@pone.0226507.ref070]\]                India                                                                                         RC             1340     1210      90,3   L
    Rahimy N. et al (2018)\[[@pone.0226507.ref071]\]           Thailand                                                                                      RC             291      234       80,4   L
    Rao P. et al (2015)\[[@pone.0226507.ref072]\]              India                                                                                         CS             862      718       83,3   L
    Sadykova L. et al (2019)\[[@pone.0226507.ref073]\]         Kazakhstan                                                                                    RC             36926    26635     72,1   L
    Schwitters A. et al (2014)\[[@pone.0226507.ref074]\]       Uganda                                                                                        CS             469      222       47,3   L
    Shahrezaei M. et al (2015)\[[@pone.0226507.ref075]\]       Iran                                                                                          RC             2224     1827      82,1   L
    Thomas B. et al (2019)\[[@pone.0226507.ref076]\]           India                                                                                         PC             455      374       82,2   A
    Wang X. et al (2015)\[[@pone.0226507.ref077]\]             China                                                                                         CS             20396    18908     92,7   L
    Wang X. et al (2017)\[[@pone.0226507.ref078]\]             China                                                                                         RC             395      296       74,9   L
    Wen Y. et al (2018)\[[@pone.0226507.ref079]\]              China                                                                                         RC             22998    21851     95,0   G
    Xiao-chun H. et al (2017)\[[@pone.0226507.ref080]\]        China                                                                                         RC             5663     3154      55,7   L
    Yoon Y. et al (2016)\[[@pone.0226507.ref081]\]             Korea                                                                                         PC             661      512       77,5   L
    Zhang Q. et al (2014)\[[@pone.0226507.ref082]\]            Kuwait                                                                                        RC             954      676       70,9   L
  **TB studies in Europe**                                                                                                                                                                            
    Aibana O. et al (2018)\[[@pone.0226507.ref083]\]           Ukraine                                                                                       RC             296      193       65,2   L
    Cruz-Ferro E. et al (2014)\[[@pone.0226507.ref084]\]       Spain                                                                                         CS             18660    16524     88,6   L
    Dias M. et al (2017)\[[@pone.0226507.ref085]\]             Portugal                                                                                      RC             17655    14186     80,4   L
    Gaborit B. et al (2017)\[[@pone.0226507.ref086]\]          France                                                                                        CC             134      112       83,6   L
    Holden I. et al (2019)\[[@pone.0226507.ref087]\]           Denmark                                                                                       RC             1681     1353      80,5   A
    Karo B. et al (2015)\[[@pone.0226507.ref088]\]             Union eropea                                                                                  RC             250864   196835    78,5   G
    Lucenko I. et al (2014)\[[@pone.0226507.ref089]\]          Latvia                                                                                        RC             2476     2167      87,5   G
    Moreno-Gómez M. et al (2014)\[[@pone.0226507.ref090]\]     Spain                                                                                         PC             146      62        42,5   L
    Priedeman M. et al (2018)\[[@pone.0226507.ref091]\]        Ukraine                                                                                       RC             1618     1327      82,0   L
    Przybylski G. et al (2014)\[[@pone.0226507.ref092]\]       Poland                                                                                        PC             2025     1813      89,5   G
    Rodríguez E. et al (2015)\[[@pone.0226507.ref093]\]        Spain                                                                                         RC             5880     4703      80,0   L
  **TB studies in Oceania**                                                                                                                                                                           
    Alo A. et al (2014)\[[@pone.0226507.ref094]\]              Fiji                                                                                          CS             395      322       81,5   L
    Itogo N. et al (2014)\[[@pone.0226507.ref095]\]            Solomon Islands                                                                               RC             4137     3779      91,3   L
    Scheelbeek P. et al (2014)\[[@pone.0226507.ref096]\]       Indonesia                                                                                     RC             1582     1244      78,6   L
    Tagaro M. et al (2014)\[[@pone.0226507.ref097]\]           Vanuatu                                                                                       RC             568      469       82,6   L
  **TB / HIV coinfection studies**                                                                                                                                                                    
    Agbor A. et al (2014)\[[@pone.0226507.ref098]\]            Cameroon                                                                                      RC             337      205       60,8   L
    Ambadekar N. et al (2015)\[[@pone.0226507.ref099]\]        India                                                                                         PC             11620    9731      83,7   L
    Belayneh M. et al (2015)\[[@pone.0226507.ref100]\]         Ethiopia                                                                                      CS             342      242       70,8   L
    Do Prado T. et al (2016)\[[@pone.0226507.ref101]\]         Brazil                                                                                        CS             68295    37445     54,8   L
    Engelbrecht M. et al (2017)\[[@pone.0226507.ref102]\]      South Africa                                                                                  CS             66940    51668     77,2   L
    Jacobson K. et al (2015)\[[@pone.0226507.ref103]\]         South Africa                                                                                  CS             657      540       82,2   L
    Lawal A. et al (2018)\[[@pone.0226507.ref104]\]            Nigeria                                                                                       RC             1382     745       53,9   A
    Mahtab S. et al (2017)\[[@pone.0226507.ref105]\]           South Africa                                                                                  CS             12672    8870      70,0   G
    Monge S. et al (2014)\[[@pone.0226507.ref106]\]            Spain                                                                                         PC             271      216       79,7   G
    Parchure R. et al (2016)\[[@pone.0226507.ref107]\]         India                                                                                         RC             769      450       58,5   G
    Sinshaw Y. et al (2017)\[[@pone.0226507.ref108]\]          Ethiopia                                                                                      CS             308      238       77,3   G
    Tanue E. et al (2019)\[[@pone.0226507.ref109]\]            Cameroon                                                                                      RC             1041     818       78,6   A
    Theingi P. et al (2017)\[[@pone.0226507.ref110]\]          Myanmar                                                                                       RC             815      624       76,6   G
    Torrens A. et al (2016)\[[@pone.0226507.ref111]\]          Brazil                                                                                        RC             7628     3664      48,0   L
    Wannheden C. et al (2014)\[[@pone.0226507.ref112]\]        Sweden                                                                                        RC             127      109       85,8   G
  **TB / Children studies**                                                                                                                                                                           
    Alavi S. et al (2015)\[[@pone.0226507.ref113]\]            Iran                                                                                          CS             177      144       81,4   L
    Flick R. et al (2016)\[[@pone.0226507.ref114]\]            Malawi                                                                                        RC             371      228       61,5   G
    Hamid M. et al (2019)\[[@pone.0226507.ref115]\]            Pakistan                                                                                      RC             1665     1421      85,3   A
    Laghari M. et al (2018)\[[@pone.0226507.ref116]\]          Pakistan                                                                                      RC             2111     1950      92,4   L
    Ohene S. et al (2019)\[[@pone.0226507.ref117]\]            Ghana                                                                                         RC             214      194       90,7   L
    Tilahun G. et al (2016)\[[@pone.0226507.ref118]\]          Ethiopia                                                                                      RC             491      420       85,5   L
    Turkova A. et al (2016)\[[@pone.0226507.ref119]\]          European Union, Thailand, Brazil                                                              CS             127      116       91,3   L
  **MDR/XDR-TB studies**                                                                                                                                                                              
    Addis K. et al (2017)\[[@pone.0226507.ref120]\]            Ethiopia                                                                                      RC             242      154       63,6   L
    Aibana O. et al (2017)\[[@pone.0226507.ref121]\]           Ukraine                                                                                       RC             378      65        17,2   L
    Altena R. et al (2015)\[[@pone.0226507.ref122]\]           Netherlands                                                                                   CS             113      89        78,8   L
    Atif M. et al (2017)\[[@pone.0226507.ref123]\]             Pakistan                                                                                      RC             80       48        60,0   L
    Bastard M. et al (2018)\[[@pone.0226507.ref124]\]          Abkhazia, Armenia, Colombia, Kenya, Kyrgyzstan, Swaziland and Uzbekistan                      RC             1369     872       63,7   L
    Brust J. et al (2018)\[[@pone.0226507.ref125]\]            South Africa                                                                                  PC             206      140       68,0   L
    Cegielski J. et al (2015)\[[@pone.0226507.ref126]\]        Estonia, Latvia, Philippines, Peru, Russia, South Africa, South Korea, Taiwan, and Thailand   PC             1244     722       58,0   L
    Chen Y. et al (2018)\[[@pone.0226507.ref127]\]             China                                                                                         RC             284      194       68,3   G
    Chiang S. et al (2016)\[[@pone.0226507.ref128]\]           Peru                                                                                          RC             232      163       70,3   L
    Demile B. eta al (2018)\[[@pone.0226507.ref129]\]          Ethiopia                                                                                      CS             381      264       69,3   L
    Duraisamy K. et al (2014)\[[@pone.0226507.ref130]\]        India                                                                                         RC             179      112       62,6   G
    Francis J. et al (2018)\[[@pone.0226507.ref131]\]          Australia                                                                                     RC             244      161       66,0   G
    Heysell S. et al (2016)\[[@pone.0226507.ref132]\]          Russia                                                                                        PC             98       51        52,0   L
    Ibrahim E. et al (2016)\[[@pone.0226507.ref133]\]          Egypt                                                                                         RC             577      352       61,0   L
    Jagielski T. et al (2014)\[[@pone.0226507.ref134]\]        Poland                                                                                        PC             46       8         17,4   L
    Janmeja A. et al (2018)\[[@pone.0226507.ref135]\]          India                                                                                         RC             256      132       51,6   L
    Javaid A. et al (2016)\[[@pone.0226507.ref136]\]           Pakistan                                                                                      RC             186      73        39,2   L
    Javaid A. et al (2017)\[[@pone.0226507.ref137]\]           Pakistan                                                                                      RC             535      406       75,9   L
    Jensenius M. et al (2016)\[[@pone.0226507.ref138]\]        Norway                                                                                        RC             89       45        50,6   L
    Kawatsu L. et al (2018)\[[@pone.0226507.ref139]\]          Japan                                                                                         CS             172      98        57,0   L
    Khan M. et al (2015)\[[@pone.0226507.ref140]\]             Pakistan                                                                                      RC             179      133       74,3   L
    Liu Q. et al(2018) \[[@pone.0226507.ref141]\]              China                                                                                         RC             139      84        60,4   L
    Marais E. et al (2014)\[[@pone.0226507.ref142]\]           South Africa                                                                                  RC             351      158       45,0   L
    Monserrat L. et al (2017)\[[@pone.0226507.ref143]\]        Mexico                                                                                        RC             507      399       78,7   L
    Munoz-Torrico M. et al(2016)\[[@pone.0226507.ref144]\]     Mexico                                                                                        RC             90       33        36,7   A
    Nair D. et al (2017)\[[@pone.0226507.ref145]\]             India                                                                                         RC             788      469       59,5   L
    Pang Y. et al (2017)\[[@pone.0226507.ref146]\]             China                                                                                         RC             29       7         24,1   L
    Parmar M. et al (2018)\[[@pone.0226507.ref147]\]           India                                                                                         RC             3712     781       21,0   L
    Phuong N. et al (2016)\[[@pone.0226507.ref148]\]           Viet Nam                                                                                      RC             1380     1008      73,0   L
    Schnippel K. et al (2015)\[[@pone.0226507.ref149]\]        South Africa                                                                                  RC             10763    4227      39,3   L
    Trébucq A. et al (2018)\[[@pone.0226507.ref150]\]          Central Africa                                                                                PC             1006     821       81,6   L
    Udwadia Z. et al (2014)\[[@pone.0226507.ref151]\]          India                                                                                         PC             78       53        67,9   L
    Verdecchia M. et al (2018)\[[@pone.0226507.ref152]\]       Swaziland                                                                                     RC             174      131       75,3   L
    Viana P. et al (2018)\[[@pone.0226507.ref153]\]            Brazil                                                                                        PC             257      139       54,1   G
    Villegas L. et al (2016)\[[@pone.0226507.ref154]\]         Peru                                                                                          RC             1039     815       78,4   G
    Xu C. et al (2017)\[[@pone.0226507.ref155]\]               China                                                                                         RC             1542     734       47,6   G
    Zhang L. et al (2017)\[[@pone.0226507.ref156]\]            China                                                                                         PC             537      374       69,6   L
    Zhang Q. et al (2016)\[[@pone.0226507.ref157]\]            China                                                                                         RC             160      88        55,0   L

CC: Cases and controls study; CS: cross section study: PC: prospective cohort study; RP: retrospective cohort study; A: Acceptable; G: Good; L: Low.

Results of TB treatment {#sec012}
-----------------------

The success rate for the treatment of drug-sensitive TB in adults was 80.1% (95% CI: 78.4--81.7) ([Fig 2](#pone.0226507.g002){ref-type="fig"}). A high degree of heterogeneity (I^2^: 99.8%) was observed among the studies, but no publication bias was found in the funnel plot. Based on the subgroup analysis, America had the lowest treatment success rate at 75.9% (95% CI: 73.8--77.9) ([S1 Fig](#pone.0226507.s002){ref-type="supplementary-material"}), followed by Africa at 78.9% (95% CI: 75.5--82.2) ([S2 Fig](#pone.0226507.s003){ref-type="supplementary-material"}), Europe at 79.7% (95% CI: 76.2--83.0) ([S3 Fig](#pone.0226507.s004){ref-type="supplementary-material"}), Asia at 81.6% (95% CI: 78.5--84.5) ([S4 Fig](#pone.0226507.s005){ref-type="supplementary-material"}) and Oceania at 83.9% (95% CI: 75.2--91.0) ([S5 Fig](#pone.0226507.s006){ref-type="supplementary-material"}).

![Pooled estimate of successful tuberculosis treatment outcome.](pone.0226507.g002){#pone.0226507.g002}

The success rate was 84.8% in children (95% CI: 77.7--90.7) ([S6 Fig](#pone.0226507.s007){ref-type="supplementary-material"}), 71.0% in patients coinfected with HIV (95% CI: 63.7--77.8) ([S7 Fig](#pone.0226507.s008){ref-type="supplementary-material"}), 58.4% in patients with MDR-TB (95% CI: 51.4--64.6) ([S8 Fig](#pone.0226507.s009){ref-type="supplementary-material"}) and 27.1% (95% CI: 12.7--44.5) in patients with XDR-TB ([Table 3](#pone.0226507.t003){ref-type="table"}). A high degree of heterogeneity (I^2^: 98%; I^2^: 99.8%; I^2^: 99.2%; I^2^: 84.3%, respectively), was observed in these subgroups, but there was no evidence of publication bias in the funnel plot.

10.1371/journal.pone.0226507.t003

###### Success rate in patients with XDR-TB.

![](pone.0226507.t003){#pone.0226507.t003g}

  Autor (Year)                n     Success (%)   95% CI         Weight (%)
  --------------------------- ----- ------------- -------------- ------------
  Chen Y. et al (2018)        35    57,1          39,3 to 73,7   20,1
  Pang Y. et al (2017)        29    24,1          10,3 to 43,5   19,4
  Cegielski J. et al (2015)   58    29,3          18,1 to 42,7   21,4
  Aibana O. et al (2017)      35    5,7           0,7 to 19,2    20,1
  Javaid A. et al (2017)      26    23,1          8,9 to 43,6    19,1
  Total (fixed effects)       183   27,5          21,3 to 34,5   100
  Total (random effects)      183   27,1          12,7 to 44,5   100

Predictors of TB treatment success {#sec013}
----------------------------------

Patients who were smear-negative at two months of treatment were almost three times more likely to succeed in treatment (OR 2.7; 1.5--4.8) ([Fig 3](#pone.0226507.g003){ref-type="fig"}), whereas patients who were younger than 65 years (OR 2.0; 1.7--2.4) ([Fig 4](#pone.0226507.g004){ref-type="fig"}), nondrinkers (OR 2.0; 1.6--2.4) ([Fig 5](#pone.0226507.g005){ref-type="fig"}) and HIV-negative (OR 1.9; 1.6--2.3) were two times more likely to succeed in treatment. In contrast, diabetes, the TB form and positive baseline sputum smear did not influence the results of treatment ([Table 4](#pone.0226507.t004){ref-type="table"}).

![Pooled estimate to negative smear in the 2nd month as a factors predictive of favorable outcomes of tuberculosis treatment.](pone.0226507.g003){#pone.0226507.g003}

![Pooled estimate to age \<65 years as a factors predictive of favorable outcomes of tuberculosis treatment.](pone.0226507.g004){#pone.0226507.g004}

![Pooled estimate to Non-alcoholic as a factors predictive of favorable outcomes of tuberculosis treatment.](pone.0226507.g005){#pone.0226507.g005}

10.1371/journal.pone.0226507.t004

###### Factors predictive of favorable outcomes of tuberculosis treatment.

![](pone.0226507.t004){#pone.0226507.t004g}

                                    Included studies   Exposed        Not exposed     Odds ratio   95% CI
  --------------------------------- ------------------ -------------- --------------- ------------ ----------
  Negative smear in the 2nd month   9                  8715/12233     4082/7077       2.7          1.5--4.8
  Age \<65 years                    15                 32384/36587    6937/8127       2.0          1.7--2.4
  Non-alcoholic                     9                  18074/30334    4118/7609       2.0          1.6--2.4
  HIV Negatives                     35                 51769/64024    43781/76845     1.9          1.6--2.3
  New cases                         34                 86862/122085   17595/31183     1.6          1.5--1.6
  No smoking                        16                 22336/26922    15092/19442     1.5          1.3--1.7
  Urban residence                   27                 52617/78278    23016/28380     1.2          1.0--1.4
  Female sex                        61                 74645/95809    128387/173218   1.2          1.1--1.3
  No Diabetes                       11                 34836/53800    4161/5482       1.1          0.9--1.5
  Pulmonary Tuberculosis            34                 83906/118231   27509/42250     1.1          0.9--1.3
  Positive smear on admission       15                 39422/57407    31945/46381     1.0          08--1.2

Discussion {#sec014}
==========

This meta-analysis showed that the success rate for the treatment of drug-sensitive TB in adults was 80.1% (95% CI: 78.4--81.7); for those with associated HIV-TB, it was 71.0% (95% CI: 63.7--77.8), In patients with XDR-TB it was 27.1% (95% CI: 12.7--44.5) and for those with MDR-TB, it was 58.4% (95% CI: 51.4--64.6). These values did not differ significantly from those reported by the WHO for 2016 (82%, 77%, 34% and 55%, respectively)\[[@pone.0226507.ref001]\]. This result was expected considering that cases of TB require compulsory notification in most countries. A study in Europe (2005), reported a pooled estimate of successful outcomes of 74.4% (95% CI 71.0--77.9%), this lower estimate than the one reported in this review could be attributed to the fact that the studies analyzed in this work are prior to 2005 \[[@pone.0226507.ref158]\]. While, another study in Ethiopia, reported a global success rate of combined TB treatment of 86% (with a 95% CI: 83%-88%), higher than our estimate of successful treatment \[[@pone.0226507.ref159]\]. To XDR and MDR TB a review published in 2017 reported pooled treatment success of 26% and 60% respectively, which is not different from our results\[[@pone.0226507.ref160]\]. However, these results should be improved to cure 90% of patients. The results of tuberculosis treatment improve with the use of adherence interventions, such as patient education and counseling, incentives and enablers, psychological interventions, reminders and tracers, and digital health technologies. Therefore, tuberculosis control programs should keep in mind that in addition to prescribing tuberculosis medications, they need to include resources to help patients overcome individual challenges to complete treatment \[[@pone.0226507.ref161]\].

In children, the treatment success rate was 83.4% (95% CI: 71.0--92.9). The WHO annual Global Tuberculosis Report does not specify a treatment success rate for children. However, studies from varying countries published in 2016 reported success rates for the treatment of children with TB that were both lower and higher than that those estimated in this review, e.g., 61.5% in Malawi and 91.3% in the European Union\[[@pone.0226507.ref114],[@pone.0226507.ref119]\]. Although in 2018 a review was published that calculated the success rate of 78% to MDR TB treatment in children\[[@pone.0226507.ref162]\], this is the first pooled estimate of treatment of drug-sensitive TB success in children at the global level in the last five years.

Sputum smear conversion in the second month of treatment was previously associated with treatment success\[[@pone.0226507.ref163]\]. This meta-analysis confirmed that a negative sputum smear at two months of treatment was a predictor of success (OR 2.7; 95% CI: 1.5--4.8). However, sputum smear non-conversion after two months of treatment continues to be controversial as a predictor of unfavorable outcomes due to its low sensitivity and specificity for identifying treatment failure\[[@pone.0226507.ref164]\]. Therefore, further studies are needed to clarify this controversy.

It was also confirmed that factors such as age \<65 years (OR 2.0; 95% CI 1.7--2.4), female sex (OR 1.2; 95% CI 1.1--1.3) and a new case type favor the success of TB treatment, as reported in previous studies\[[@pone.0226507.ref008],[@pone.0226507.ref009],[@pone.0226507.ref017],[@pone.0226507.ref048],[@pone.0226507.ref068],[@pone.0226507.ref069],[@pone.0226507.ref086],[@pone.0226507.ref138]\]. Not drinking alcohol was also a predictor of favorable treatment results (OR 2.0; 95% CI 1.6--2.4). Alcohol consumption has been associated with treatment failure and a predisposition toward adverse drug effects, either because those who consumed alcohol skipped more doses during TB treatment or because alcohol may affect the immune response against *M*. *tuberculosis*, leading to treatment failure or a late response to treatment\[[@pone.0226507.ref044],[@pone.0226507.ref092],[@pone.0226507.ref130]\].

Nonsmokers also had a higher probability of treatment success (OR 1.5; 95% CI: 1.3--1.7) according to a study conducted in China that suggested smoking adversely affects the bacteriological response to and the result of TB treatment\[[@pone.0226507.ref053]\]. In Malaysia, smoking was also identified as a risk factor for unfavorable treatment outcomes\[[@pone.0226507.ref061]\]. In Poland, smoking did not influence the results of TB treatment\[[@pone.0226507.ref092]\]. In Brazil patients with a history of smoking increase 2.1 (95% CI 1.1--4.1) times, but the possibility of failure in TB treatment. Moreover, having a larger age of 50 years shows that the possibility of failure increases 2.8 (95% CI 1.4--6.0)\[[@pone.0226507.ref165]\].

The HIV-TB association continues to be a challenge for public health. Studies have identified coinfection as a risk factor for unfavorable TB treatment results, and most have attributed these results to the high mortality in these patients\[[@pone.0226507.ref010],[@pone.0226507.ref098]--[@pone.0226507.ref100],[@pone.0226507.ref105],[@pone.0226507.ref109]\]. We corroborated these results, showing that HIV-negative patients had a higher proportion of favorable treatment outcomes (OR 1.9; 95% CI 1.6--2.3), while in general, the treatment success rate in coinfected patients was low (70.5%).

In this review, diabetes did not influence treatment outcomes. Our results coincide with those reported in Georgia and Malaysia\[[@pone.0226507.ref040],[@pone.0226507.ref061]\], although it was previously suggested that diabetes was associated with unfavorable TB treatment results\[[@pone.0226507.ref056],[@pone.0226507.ref081]\].

Among the limitations of this study, it is necessary to mention that the use of observational studies for a meta-analysis could induce errors by finding false significant associations when combining small studies affected by confounding\[[@pone.0226507.ref166]\]. Additionally, it is known that the quality of a meta-analysis depends on the quality of the included studies; in most studies, the quality was classified as low, which may be associated with the fact that most of the studies were retrospective and based on mandatory notification systems, where it is difficult to control due to loss at follow-up and other confounding factors. The degree of heterogeneity was also high among the studies; therefore, the random effects method was used to obtain the pooled results. Finally, the methodological variations among the included studies could also compromise the results of the meta-analysis.

Conclusion {#sec015}
==========

The study findings suggest that the rate of successful TB treatment at the global level is good but is still below the defined threshold of 85%. Factors such as age, sex, alcohol consumption, smoking, sputum smear non-conversion at two months of treatment and HIV affect the results of TB treatment.
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